We are combating cancer by enabling precision cancer management
Cancer is ranked as a leading cause of death affecting billions of patients and families worldwide and was responsible for almost 10 million deaths in 2020.
That is why we want to transform cancer management and reduce cancer deaths by enabling precision medicine and better monitoring. Precision diagnostics enables the doctor to, based on the cancer’s genomic information, select the treatment that is most likely to work. Our unique technology enables sensitive detection of cancer mutations by a simple blood sample.
By sensitive monitoring of the disease, we have a chance to save the life of patients.
Detection of circulating tumor DNA in liquid biopsies
Using our technology, it is possible to detect circulating tumor DNA from a simple blood sample. Due to turnover and cell death, all cancers release small amounts of tumor-specific DNA into the blood and other body fluids as circulating tumor DNA. Multiple publications have proven the SiMSen-Seq technology is able to detect low-frequent circulating tumor DNA robustly and accurately in liquid biopsies.
Compared to tissue biopsy that is the standard in cancer management to retain genetic information of a tumor, a liquid biopsy is:
The impact of circulating tumor DNA detection
Detection of circulating tumor DNA
Interesting in evaluating?
Simsen Diagnostics technology for ctDNA is easy to run in any molecular laboratory. Our evaluation kit constructs a sequencing library from eight amplicons inside the gene PIK3CA in a single reaction.
- Eight amplicons in PIK3CA
- 99.5% sensitivity at detecting 0.1% VAF*
- Easy to use
*When loading more than 15ng DNA